BTIG raised the firm’s price target on Organogenesis (ORGO) to $7 from $6 and keeps a Buy rating on the shares after its Q4 results. The firm is also adjusting its model to reflect forward rolled estimates and the company’s recent debt reduction, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue